Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-13

Study Completion Date

2011-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610

Posttraumatic Stress Disorder

COMPLETED PHASE2

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

NCT01458327

Posttraumatic Stress Disorder

COMPLETED PHASE2

Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury

NCT06394284

PTSD, Post Traumatic Stress Disorder Moral Injury

RECRUITING PHASE3

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

NCT06884514

Healthy

RECRUITING PHASE1

Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

NCT00402298

Posttraumatic Stress Disorder

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Posttraumatic stress disorder (PTSD) occurs after experiencing a traumatic event or events. PTSD is a public health problem that causes a great deal of suffering.

This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.

People who receive the low dose of MDMA have the opportunity to take part in a second "open label" study continuation, wherein the participants will undergo three MDMA-assisted sessions, with the participant and the researchers knowing that a full dose of MDMA is being administered. People who receive the full dose of MDMA, and any person who received low-dose MDMA and does not undergo the open-label study continuation will have PTSD symptoms measured six and twelve months after the third session. People who take part in the open label study continuation have their PTSD symptoms assessed six and 12 months after the third Phase II MDMA-assisted session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Posttraumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Full Dose MDMA-assisted therapy (125 mg)

Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA

Group Type EXPERIMENTAL

3,4-methylenedioxymethamphetamine (125 mg)

Intervention Type DRUG

Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.

Therapy

Intervention Type BEHAVIORAL

Non-directive therapy performed by a team of two co-therapists

Active Placebo MDMA-assisted therapy (25 mg)

Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA

Group Type ACTIVE_COMPARATOR

3,4-methyelendioxymethamphetamine (25 mg)

Intervention Type DRUG

Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.

Therapy

Intervention Type BEHAVIORAL

Non-directive therapy performed by a team of two co-therapists

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3,4-methylenedioxymethamphetamine (125 mg)

Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.

Intervention Type DRUG

3,4-methyelendioxymethamphetamine (25 mg)

Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.

Intervention Type DRUG

Therapy

Non-directive therapy performed by a team of two co-therapists

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MDMA MDMA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with posttraumatic stress disorder (PTSD).
* PTSD still remains after one or more prior treatment, with treatment including psychotherapy (talk therapy) or drug therapy
* May meet criteria for a mood disorder
* Must be at least 18 years old
* Must be able to stop taking psychiatric medication during the course of the study, from the start of the study to the follow-up two months after experimental session 3.
* Must agree to follow all rules and instructions relating to the experimental session, including restrictions on food and substance (alcohol and drug) consumption.
* Must be willing to stay overnight at the researcher's office after each experimental session until the non-drug session occurring the next morning.
* Must be willing to be contacted by one of the researchers on a daily basis for a week after each experimental session.
* Female participants of childbearing potential must have a negative pregnancy test and must agree to use an effective form of birth control.
* Participants must have sufficient proficiency in speaking the German language to participate in MDMA-assisted psychotherapy. Participants must be able to read documents in German.

Exclusion Criteria

* Cannot have history of or current primary psychotic disorder or bipolar affective disorder-1.
* Dissociative identity disorder, or an eating disorder with active purging or borderline personality disorder.
* Evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder. (People with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
* Uncontrolled hypertension, peripheral vascular disease, hepatic disease (with or without abnormal liver enzymes), or history of hyponatremia or hyperthermia.
* Being pregnant or lactating (nursing), or not practicing an effective method of birth control.
* Weight of less than 50 or more than 105 kg.
* Patients reporting prior use of "Ecstasy" more than 5 times or at any time within the previous 6 months.
* People who would present a serious suicide risk or who are likely to require hospitalization during the course of the study.
* People who need ongoing concomitant therapy with a psychotropic drug.
* Meeting DSM-IV criteria for substance abuse or dependence for any substance save caffeine or nicotine in the past 60 days.
* People who cannot give adequate consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No